The drug Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an antiapoptotic protein. Healthcare professionals recommend using this drug in treating patients with chronic lymphocytic leukemia (CLL) with 17p deletion. This drug comes in the form of tablets of 10 mg, 50 mg and 100 mg for oral administration. The common side effects of Venetoclax are neutropenia, diarrhoea, nausea, anaemia, upper respiratory tract infection, thrombocytopenia, and fatigue.